-
2021.12.20
Other
- RaQualia Pharma and Hisamitsu Pharmaceutical have agreed to enter into a license agreement for a novel sodium channel blocker
-
2021.12.01
Sustainability
- Announcement of Contributions to Japan Olympic Committee (JOC) and Japan Paralympic Committee (JPC)
-
2021.11.22
Sustainability
- Products to solve issues for living in Space and living on Earth “Fixpace®” Notification to be used in the International Space Station Hisamitsu
-
2021.10.14
lR Information
- Notification Regarding Application for Selection of “Prime Market” Under the New Market Segments
-
2021.10.14
lR Information
- Notification Regarding Concerning the Decision of Matters Relating to Acquisition of Company’s Own Shares
-
2021.10.14
lR Information
- FY02/2022 Q2 Results Earnings Release Presentation
-
2021.10.04
Other
- Hisamitsu Pharmaceutical Online Sales “Hisamitsu® Iki-Iki Online” Announcement of Starting Pharmaceutical Product Sales
-
2021.09.21
Other
- Announcement of Investment in GAIA Biomedicine, a Bio-Venture from Kyushu University in Japan
-
2021.09.17
Management and Personnel
- Announcement regarding Establishment of “the 7th Medium-term Management Policy” (Presentation Material)
-
2021.09.17
Management and Personnel
- Announcement regarding Establishment of “the 7th Medium-term Management Policy”
-
2021.08.31
Sustainability
- Notice regarding Support for The Disaster of The Torrential Rains in August 2021
-
2021.08.27
Sustainability
- Notice regarding Providing Relief Supplies in Response to The Torrential Rains in August 2021
-
2021.08.25
Ethical Drugs
- Notification of approval for manufacturing and marketing approval of the additional indications of cancer pain relief for pediatric patients of FENTOS® Tapes (Transdermal, pain management patch, Development code: HFT-290) in Japan Hisamitsu
-
2021.08.20
Ethical Drugs
- Notification of application for manufacturing and marketing approval of the additional indications of “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” for ZICTHORU® Tapes (Transdermal, pain treatment NSAID patch, development code: HP-3150) in Japan
-
2021.08.12
Other
- Notification of Hisamitsu Pharmaceutical Co., Inc. receiving Administrative Disposition from Saga Prefecture
-
2021.07.30
Ethical Drugs
- Notification of Transfer of Marketing Rights for ORAVI® Mucoadhesive Tablets 50mg for Oropharyngeal Candidiasis
-
2021.07.26
lR Information
- Notice regarding Determination of Details of Issuance of Stock Compensation-Type Share Options (Stock Acquisition Rights)
-
2021.07.08
lR Information
- FY02/2022 Q1 Results Earnings Release Presentation
-
2021.07.08
lR Information
- Notice regarding Issuance of Stock Compensation-Type Share Options (Stock Acquisition Rights)
-
2021.05.28
Sustainability
- Signing of Partnership Agreement with Saga Prefecture and Saga Sports Association Promotion of “SAGA Sports Pyramid Design”
-
2021.05.28
lR Information
- Approach to and Policy on Reduction of Investment Unit, etc.
-
2021.05.27
Management and Personnel
- Executive Appointments
-
2021.05.19
Ethical Drugs
- Notification of marketing of ZICTHORU® Tapes for “cancer pain” in Japan (Transdermal, pain treatment NSAID patch)
-
2021.05.18
Other
- Salonpas® Named the World’s No. 1 OTC Topical Analgesic Patch Brand for the Fifth Consecutive Year
-
2021.04.27
Research and Development
- Notification of the results of the Phase Ⅲ clinical study of HP-5070 in Japan (primary palmar hyperhidrosis treatment drug)
-
2021.04.08
lR Information
- FY02/2021 Q4 Results Earnings Release Presentation
-
2021.04.08
Management and Personnel
- Executive Appointments
-
2021.04.02
Other
- Contributions to The Japan Olympic Committee (JOC) and The Japan Paralympic Committee (JPC)
-
2021.03.31
Sustainability
- Notice regarding Designing of “HELLO! eco!” Logo and The Launch of its Website Products that meet the environmental standards set by the Company are labeled with the logo.
-
2021.03.23
Ethical Drugs
- Notification of approval for manufacturing and marketing approval of ZICTHORU® TAPES for “cancer pain” in Japan (Transdermal, pain treatment NSAID patch, development code: HP-3150)
-
2021.03.23
lR Information
- Notice regarding Revision of Earnings Forecast
-
2021.02.24
Subsidiaries and Affiliated Companies
- Noven Pharmaceuticals, Inc. press release : Noven submits New Drug Application for INVESTIGATIONAL dextroamphetamine transdermal system for ADHD
-
2021.02.12
Sustainability
- Notice regarding The Decision to Contribute to Supporting Organizations in FY 2020 through Hisamitsu Pharmaceutical Co., Inc. Hot Heart Club
-
2021.01.20
Ethical Drugs
- Notice regarding Obtaining Approval of Partial Change of Approved Matters of “Mohrus® Paps XR 120 mg and 240 mg”, Transdermal Analgesic Anti-Inflammatory Patches
-
2021.01.13
lR Information
- FY02/2021 Q3 Results Earnings Release Presentation
-
2021.01.04
Research and Development
- Notification of the commencement of the Phase III clinical study of HP-5000 in the U.S. (Transdermal, pain relief and anti-inflammatory patch)
